

1233811

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 04, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/499,634
FILING DATE: August 28, 2003
RELATED PCT APPLICATION NUMBER: PCT/US04/28000

Certified by




Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



BEST AVAILABLE COPY

Express Mail Label No. EL988554205US

Please type a plus sign (+) inside this box 


Approved for use through 7/31/2003.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

19704 U.S. PTO
60/499634
08/28/03

PROVISIONAL APPLICATION FOR PATENT COVER SHEET This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)			
Chad Gholamreza	KENNEDY EHTESHAMI	Highley, Arizona, USA Scottsdale, Arizona, USA			
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max) HYDROGELS FOR MODULATING CELL MIGRATION AND MATRIX PRODUCTION					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		26707			
OR Type Customer Number here					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City	State	ZIP			
Country	Telephone	Fax			
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		9	<input type="checkbox"/> CD(s), Number		
<input type="checkbox"/> Drawing(s) Number of Sheets			<input checked="" type="checkbox"/> Other (specify)		Return Postcard
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				\$80.00	
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		17-0055			
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE 

TYPED or PRINTED NAME Kittie A. Murray

TELEPHONE (602) 229-5200

Date 08/ 28 / 03

REGISTRATION NO.
(if appropriate)
Docket Number:

30,346

130588.00051

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Patent Application, Commissioner for Patents, Alexandria, VA 22313-1450.

1772338

16569 U.S. PTO
NO 10/20/03

Mail Label No. EL988554205US

PTO/SB/17 (5-03)

Approved for use through 10/31/2003.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 80.00

Complete if Known

Application Number
Filing Date August 28, 2003
First Named Inventor Chad Kennedy
Examiner Name
Group Art Unit
Attorney Docket No. 130588.00051

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 17-0055
Deposit Account Name Quarles & Brady LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	80.00

SUBTOTAL (1) (\$ 80.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	0.00
Multiple Dependent Claims	-3** =	X	0.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2050 65			Surcharge - late filing fee or oath	
1052 50	2052 25			Surcharge - late provisional filing fee or cover sheet	
1053 130	2053 130			Non-English specification	
1812 2,520	2812 2,520			For filing a request for <i>ex parte</i> reexamination	
1804 920	2804 920			Requesting publication of SIR prior to Examiner action	
1805 1,840	2805 1,840			Requesting publication of SIR after Examiner action	
1251 110	2251 55			Extension for reply within first month	
1252 410	2252 205			Extension for reply within second month	
1253 930	2253 465			Extension for reply within third month	
1254 1,450	2254 725			Extension for reply within fourth month	
1255 1,970	2255 985			Extension for reply within fifth month	
1401 320	2401 160			Notice of Appeal	
1402 320	2402 160			Filing a brief in support of an appeal	
1403 280	2403 140			Request for oral hearing	
1451 1,510	2451 1,510			Petition to institute a public use proceeding	
1452 110	2452 55			Petition to revive - unavoidable	
1453 1,300	2453 650			Petition to revive - unintentional	
1501 1,300	2501 650			Utility issue fee (or reissue)	
1502 470	2502 235			Design issue fee	
1503 630	2503 315			Plant issue fee	
1460 130	2460 130			Petitions to the Commissioner	
1807 50	2807 50			Processing fee under 37 CFR 1.17(q)	
1806 180	2806 180			Submission of Information Disclosure Stmt	
8021 40	28021 40			Recording each patent assignment per property (times number of properties)	
1809 750	2809 375			Filing a submission after final rejection (37 CFR § 1.129(a))	
1810 750	2810 375			For each additional invention to be examined (37 CFR § 1.129(b))	
1801 750	2801 375			Request for Continued Examination (RCE)	
1802 900	2802 900			Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00

SUBMITTED BY

Name (Print/Type) Kittie A. Murray

Signature

Kittie A. Murray

Registration No. (Attorney/Agent)

30,288

Complete (if applicable)

Telephone (602) 229-5200

Date

August 28, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1772339

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL CERTIFICATE: EL988554205US

I hereby certify that this correspondence listed below is being deposited with the United States Postal Service on the date set forth below as Express Mail in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, Alexandria, VA 22313-1450.

Date of Signature and Deposit: August 28, 2003

By: William J. Belyk
(Signature of person depositing mail)

William J. Belyk

CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. 1.10

Applicant: Kennedy *et al.*

Filed: August 28, 2003

Title: HYDROGELS FOR MODULATING CELL
MIGRATION AND MATRIX PRODUCTION

Docket No.: 130588.00051

Mail Stop Provisional Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Type of Filing:

- 1) Fee Transmittal;
- 2) Provisional Application For Patent Cover Sheet;
- 3) Specification (9 pages plus cover sheet); and
- 4) Return receipt postcard.

Express Mail Label No. EL988554205US

PROVISIONAL APPLICATION COVER SHEET
Additional Page

6/03
Approved for use through 7/31/2003.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number		130588.00051	Type a plus sign (+) inside this box →	+
INVENTOR(S)/APPLICANT(S)				
Given Name (first and middle (if any))	Family or Surname	Residence (City and either State or Foreign Country)		
Doris Stephen	HOM MASSIA	Mesa, Arizona, USA Mesa, Arizona, USA		

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

PATENT

**PROVISIONAL APPLICATION
of**

**CHAD KENNEDY
GHOLAMREZA EHTESHAMI
DORIS HOM
STEPHEN MASSIA**

For

**UNITED STATES LETTERS PATENT
on**

**HYDROGELS FOR MODULATING CELL MIGRATION
AND MATRIX PRODUCTION**

Attorneys:

**QUARLES & BRADY STREICH LANG L.L.P.
ONE RENAISSANCE SQUARE
TWO NORTH CENTRAL AVENUE
PHOENIX, AZ 85004-2391**

This paper or fee is being deposited with the
U.S. Postal Service "Express mail Post Office to
Addressee" under 37 CFR 1.10, Mailing Label
No. EL988554205US

Docket No. 130588.00051

Hydrogel for Modulating Cell Migration and Matrix Deposition

Field of the Invention

The present invention, a hydrogel consisting of a pre-gel conjugate, is intended for use in the field of medicine. Specifically, the pre-gel is comprised of dextran, peptide sequences susceptible to proteolytic cleavage and peptide or protein therapeutics. The incorporation of a cleavable peptide into a biodegradable, three-dimensional polysaccharide network regulates tissue growth by providing degradation sites for cell-released proteases. These components of the hydrogel are suited to modulate cell migration and invasion. Moreover, the pre-gel conjugate has high biocompatibility suited for use as an injectable gel following polymerization (gel formation) or polymerization in situ. Once injected, the gel can serve as a modulator to cell growth and protein synthesis, which has broad medical applications such as, tissue engineering, wound healing, cancer, limiting angiogenesis and cardiovascular disease. Addition of specific therapeutics in the gel, yields an ideal local drug delivery vehicle. Research applications include in vitro diagnostic studies of local peptide or protein effects on cell migration, invasion, proliferation, protein expression, cytotoxicity, DNA and mRNA expression, etc. The gel form could be used in diverse conditions from microarrays and biosensors to medical implants.

Background of the Invention

Hydrogels have been gaining significance as an effective biomaterial; its interactions with biological tissues or functions demonstrate high biocompatibility. Specifically, a hydrogel is a hydrophilic polymer network that can store a percentage of water [1]. This is created by forming crosslinks between polymeric strands, which can be chemically modified to react using light, heat, or pH changes. Dextran hydrogels can be prepared in this manner [2].

Of the many possible biocompatible gels, dextran gels have been recognized as a good material for experimental use and FDA approved. As a natural polymer, dextran is a polysaccharide that is biodegradable through hydrolysis or enzymatic reactions [2]. Additionally, their hydroxyl functional groups allow for chemical modification to either form cross-links in hydrogel formation or attachments to molecules [3]. As a material, dextran is inexpensive and easy to manipulate. This invention created a new kind of dextran hydrogel suited for controlled growth of tissue by adding a proteolytically cleavable peptide [4].

Degradation of hydrogels depends on hydrolysis of either the cross-links or the polymer backbone. This process is unique to the different hydrogel compositions. Some may be synthesized with targeted degradation of the cross-links or the backbone. Regular degradation of polymers in general relies on adsorption of medium on the polymer surface, diffusion of medium into the polymer, chemical reactions, diffusion of degradation products, and desorption of degradation products [5]. For the most part, degradation is mitigated by specific enzymatic hydrolysis of hydrogel components.

Meyvis et al. incorporated (endo-) dextranase during cross-linking of dextran methacrylated hydrogels in order to introduce degradable units in the polymer [6]. The degradation rate would depend on the cross-link density and the amount of dextranase present. It was shown that lower cross-link density correlated with shorter degradation times. A similar method was employed by O. Franssen et al. to produce degradation-controlled release of proteins [7]. Enzymatically-degrading dextran hydrogels were made by co-entrapment of dextranase. In addition, chemically degrading gels of hydroxyethyl methacrylated dextran were obtained to demonstrate degradation time with cross-linking. Mann and West et al. produced proteolytically degradable domains within hydrogels to promote degradation of the cross-links [4].

The introduction of the cleavable peptide is intended to modulate the migration of cells. Cell migration is mitigated by response to extracellular signals and phenotypic preference; this concept is an established notion in cell biology. Through chemotaxis, the cells move in a direction controlled by a gradient of diffusible chemicals [8]. In cases of injury, this effect is brought about by signaling from the immune

system. For vascular injury following angioplasty, the response of smooth muscle cells to injury signals leads to accumulation of neointimal smooth muscle cells. Cell migration studies are typically conducted in experimental assays with modified Boyden chambers. These chambers have inserts that separate cells from chemoattractants in the lower well. The chemical signaling causes the migration of cells through micron size pores; these pore sizes and density may be specific for each type of cell.

The movement of cells to the extracellular matrix is facilitated by the release of matrix metalloproteinases (MMPs) to dissolve numerous pericellular substrates [8]. These extracellular proteinases are able to degrade structural proteins of the extracellular matrix (ECM), cleave cell surface molecules, and other proteins. This regulates cell behavior in response to physiological processes including embryonic development, wound repair, cancer, and tissue morphogenesis [8]. Since their identification, several classes of MMPs have been discovered to function in different ways; some specifically target amino acid residues to remove barriers to invasion. Tissue inhibitors of metalloproteinases (TIMPs) are naturally occurring inhibitors of MMPs [9]. Four known TIMP isoforms, TIMP-1, -2, -3, and -4, have been studied for their binding affinity to different MMPs. TIMPs inhibit MMP activity by binding to them, producing an inactive 1:1 complex [10]. By targeting MMP activity, tissue regulation may be possible.

Summary of the Invention

The dextran hydrogel was synthesized and tested in a combination of steps. Cell migration assays were used to validate the concept. The peptide was synthesized by the ASU Protein Chemistry Facility by Dr. Daniel Brune and Dr. John Lopez. Polypeptides were synthesized on Fmoc-XAL-PEG-polystyrene resin on a Miligen-Bioscience 9050 peptide synthesizer using standard Fmoc chemistry with HATU (*N*-[(dimethylamino)-1*H*-1,2,3-triazolo[4,5-*b*]pyridino-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide, Applied Biosystems) as the activator. After synthesis, peptides were cleaved from the synthesis resin with trifluoroacetic acid containing 2.5% triisopropyl silane and 2.5% ethanedithiol as scavengers. The peptides were then precipitated and washed 3 times with diethyl ether and vacuum dried overnight. The molecular masses of the peptides were confirmed using mass spectroscopy. The final sequence synthesized is Cys-Gly-Gly-Leu-Gly-Pro-Ala-Gly-Gly-Lys-Gly (CGGLGPAGGKG).

To synthesize the conjugated dextran, oxidized dextran (20% oxidized) is reacted with peptide in phosphate buffer. For a yield of 100 mg of conjugated dextran, 0.1 g peptide is reacted with 0.1 g dextran; this determination results from an approximated ratio. It is assumed that the molecular weight of dextran is 40 kD and the peptide is 872 MW. The two reactants are mixed well in 2 mL of phosphate buffer. The reaction is allowed for 48 hours. Six hours prior to completion, 0.02 g NaBH₄ is added to reduce possible disulfide bond formations between the peptides. To purify the product, the entire solution is placed in a dialysis bag (Snakeskin Pleated Dialysis Tubing Product, 10,000 MW cut-off). Dialysis is run for two days with the water changed every few hours to facilitate the diffusion of unreacted elements.

To synthesize the hydrogel, the conjugated dextran is reacted with acryloylated dextran (degree of substitution is 20%) in phosphate buffered saline (Gibco, without calcium chloride and magnesium chloride). A photo initiator is prepared through dissolution of 300 mg 2,2-dimethoxy-2-phenylacetophenone (Aldrich 19,611-8) in 1 mL of *N*-vinylpyrrolidone (Aldrich V340-9). An ultraviolet ray lamp (B-100AP Ultra-Violet Products, Inc., Upland, CA) of peak wavelength 370 nm was used to initiate cross-linking between the conjugated dextran and acryloylated dextran.

To validate the effectiveness of the hydrogel as a barrier, a cell migration assay was conducted. Bovine endothelial cells (CRL GMC 7372B, NIGMS Human Genetic Cell Repository) were maintained in minimum essential medium (MEM) (Gibco, 10370-021) supplemented with 10% FBS (Gemini-Bioproducts, 100-106), 1% antibiotic-antimycotic (Gibco, 15240-062), and 1% L-glutamine (Gibco, 25030081) in 5% CO₂. The cell migration assay was conducted on a 24-well plate (BD Falcon™ HTS Fluoroblok Multiwell Insert System, 8 μm pore size) with a light-opaque membrane of PET. The plates were first pre-wetted with 0.5 mL of 1% triton X-100 in PBS in order to improve the affinity of the polystyrene sides of the insert to the hydrogel. The different ratios of dextran and photo initiator were

dissolved in PBS at the 20 wt%. To produce a 1 mm thick gel, 30 μ L of the gel mixture is pipetted into each well.

Preparation of the cells for use involves exposing cells to a 3 mL solution containing fluorescent probe (CellTracker™ Probes by Molecular Probes, C-2925, C-7025). The cells are incubated for 30 minutes and the working solution is replaced with fresh media afterwards. Preparation of the cells for use involves exposing cells to a 3 mL solution containing fluorescent probe (CellTracker™ Probes by Molecular Probes, C-2925, C-7025). The cells are incubated for an additional 30 minutes. Cells are detached using 0.25% trypsin, 1% EDTA, pelleted, counted and resuspended in serum free media at a concentration of 1×10^6 cells/mL. The cells are seeded on top of the hydrogels in a volume of 300 μ L. The lower wells are filled with 1000 μ L of supplemented media via the access ports.

Endothelial cell migration is quantified by fluorescent microscopy at 4 hours, 24 hours, and 48 hours. Three randomized pictures of each well will be taken and stored for image analysis. Using National Instruments IMAQ Vision Builder 6, the percentage of migrated cells is determined as the average of three images. The cell area is represented as the percentage of the image area. ANOVA techniques are performed using a $\alpha=0.05$ to determine significant difference between hydrogel ratios.

Details

The invention is further described with reference to Appendix A: "Dextran-Based Hydrogel to Regulate Tissue Growth" by Hom, D.C., Kennedy, Chad E., Ehteshami, G. and Massia, S.P., the entire contents of which are hereby incorporated by reference.

Bibliography

- [1] Hoffman, A.S., Hydrogels for Biomedical Applications. *Advanced Drug Delivery Reviews*. 2002. 43: 3-12.
- [2] E. Schadht, B. Bogdanov, A. V. Den Bulcké, N. De Rooze, "Hydrogels prepared by crosslinking of gelation with dextran dialdehyde," *Reactive & Functional Polymers.*, vol. 33, no. 2, pp. 109-116, Aug. 1997.
- [3] W. N. E. van Dijk-Wolthuis, O. Franssen, H. Talsma, M. J. van Steenbergen, J. J. Kettenes-van den Bosch, W. E. Hennink, "Synthesis, characterization, and polymerization of glycidial methacrylate derivatized dextran," *Macromolecules.*, vol. 28, no 18, pp. 6317-6322, 1995.
- [4] B. K. Mann, A. S. Gobin, A. T. Tsai, R. H. Schmedlen, J. L. West, "Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering," *Biomaterials.*, vol. 22, no 22, pp. 3045-3051, Nov. 2001.
- [5] Gumargalieva, K.Z.; Zaikov, G.E. *Biodegradation and Biodeterioration of Polymers: Kinetical Aspects*. New York: Nova Science Publishers; 1998.
- [6] Meyvis, T et al., On the Release of Proteins from Degrading Dextran Methacrylate Hydrogels and the Correlation with the Rheologic Properties of the Hydrogels. *Pharmaceutical Research*, 2001. 18: 1593-1599.
- [7] O. Franssen. L et al., Degradable Dextran Hydrogels: Controlled Release of a Model Protein from Cylinders and Microspheres. *Journal of Controlled Release*. 1999. 60: 211-221.
- [8] Alberts Sternlicht, M.D., Werb, Z. How Matrix Metalloproteinases Regulate Cell Behavior. *Annu. Rev. Cell Dev. Biol.* 2001. 17: 463-516.
- [9] Brew, K., Dinakarpanian, D., Nagase, H. Tissue Inhibitors of Metalloproteinases: Evolution, Structure, and Function. *Biochimica et Biophysica Acta*. 2000. 1477: 267-283.
- [10] Gomis-Ruth, F.X. et al. Mechanisms of Inhibition of the Human Matrix Metalloproteinase Stromelysin-1 by TIMP-1. *Nature*. 1997. 389: 77-81.

APPENDIX A

Dextran-Based Hydrogel to Regulate Tissue Growth

D.C. Hom, Chad E. Kennedy, G. Ehteshami, S.P. Massia¹
Harrington Department of Bioengineering, Arizona State University, AZ, USA¹

Abstract—A dextran hydrogel was synthesized from cross-linking a blend of acryloylated dextran and dextran bioconjugate. The conjugated dextran contains a matrix metalloproteinase (MMP) sensitive peptides forming crosslinks that promotes cell-induced enzymatic degradation of the hydrogel and migration through the gel. By changing the ratio of cleavable cross-links to stable cross-links in the hydrogel, the extent of cell invasion into the gel (tissue ingrowth) can be regulated. At twenty-four hours, the extent of migration ranged from 0.25 to 13.6% area covered by cells based on the level of degradable crosslinks within the gel. It was discovered that the gel proportion containing 80% acryloylated dextran and 20% conjugated dextran limited the most cell migration.

Keywords—Cell migration, dextran

I. INTRODUCTION

Vascular complications create the need for improved treatment methods in percutaneous transluminal coronary angioplasty (PCTA). These complications include stent thrombosis, in-stent restenosis, and intimal hyperplasia [1-2]. Stent coatings of hydrogels which regulate tissue growth may prolong initial therapeutic benefit gained from the procedure. Modification of existing stent technology provides opportunities for direct interaction with the body's healing responses. This characteristic, combined with established understanding of stent deployment, can produce a device better suited for treating cardiovascular disease.

Of the many possible biocompatible gels, dextran gels have been recognized as a good material for experimental use. As a natural polymer, dextran is a polysaccharide that is biodegradable through hydrolysis or enzymatic reactions [3]. Additionally, their hydroxyl functional groups allow for chemical modification to either form cross-links in hydrogel formation or attachments to molecules [4-5]. As a material, dextran is inexpensive and easy to manipulate. The goal of this study is to create a new kind of dextran hydrogel suited for controlled growth of tissue by adding a degradable peptide [6].

II. METHODOLOGY

The dextran hydrogel was synthesized and tested in a combination of steps. Cell migration assays were used to validate the concept.

1) *Synthesis of peptide*: The peptide was synthesized by the ASU Protein Chemistry Facility by Dr. Daniel Brune

and Dr. John Lopez. Polypeptides were synthesized on Fmoc-XAL-PEG-polystyrene resin on a Miligen-Bioscience 9050 peptide synthesizer using standard Fmoc chemistry with HATU (*N*-[(dimethylamino)-1*H*-1,2,3-triazolo[4,5-*b*]pyridino-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide, Applied Biosystems) as the activator. After synthesis, peptides were cleaved from the synthesis resin with trifluoroacetic acid containing 2.5% triisopropyl silane and 2.5% ethanedithiol as scavengers. The peptides were then precipitated and washed 3 times with diethyl ether and vacuum dried overnight. The molecular masses of the peptides were confirmed using mass spectroscopy. The final sequence synthesized is Cys-Gly-Gly-Leu-Gly-Pro-Ala-Gly-Gly-Lys-Gly (CGGLGPAGGKG).

2) *Synthesis of conjugated dextran*: Oxidized dextran (20% oxidized) is reacted with peptide in phosphate buffer. For a yield of 100 mg of conjugated dextran, 0.1 g peptide is reacted with 0.1 g dextran; this determination results from an approximated ratio. It is assumed that the molecular weight of dextran is 40 kD and the peptide is 872 MW. The two reactants are mixed well in 2 mL of phosphate buffer. The reaction is allowed for 48 hours. Six hours prior to completion, 0.02 g NaBH₄ is added to reduce possible disulfide bond formations between the peptides.

To purify the product, the entire solution is placed in a dialysis bag (SnakeSkin Pleated Dialysis Tubing Product, 10,000 MW cut-off). Dialysis is run for two days with the water changed every few hours to facilitate the diffusion of unreacted elements.

3) *Synthesis of dextran hydrogel*: The conjugated dextran is reacted with acryloylated dextran (degree of substitution is 20%) in phosphate buffered saline (Gibco, without calcium chloride and magnesium chloride). A photoinitiator is prepared through dissolution of 300 mg 2,2-dimethoxy-2-phenyl-acetophenone (Aldrich 19,611-8) in 1 mL of *N*-vinylpyrrolidone (Aldrich V340-9). An ultraviolet ray lamp (B-100AP Ultra-Violet Products, Inc., Upland, CA) of peak wavelength 370 nm was used to initiate cross-linking between the conjugated dextran and acryloylated dextran.

4) *Cell migration assay*: Bovine endothelial cells (CRL GMC 7372B, NIGMS Human Genetic Cell Repository) are maintained in minimum essential medium (MEM) (Gibco, 10370-021) supplemented with 10% FBS (Gemini-Bioproducts, 100-106), 1% antibiotic-antimycotic (Gibco, 15240-062), and 1% L-glutamine (Gibco, 25030081) in 5% CO₂.

The cell migration assay was conducted on a 24-well plate (BD Falcon™ HTS Fluoroblock Multiwell Insert System, 8 μ m pore size) with a light-opaque membrane of PET. The plates were first pre-wetted with 0.5 mL of 1% triton X-100 in PBS in order to improve the affinity of the polystyrene sides of the insert to the hydrogel. The different ratios of dextran and photoinitiator were dissolved in PBS at the 20 wt%. To produce a 1 mm thick gel, 30 μ L of the gel mixture is pipetted into each well.

Preparation of the cells for use involves exposing cells to a 3 mL solution containing fluorescent probe (CellTracker™ Probes by Molecular Probes, C-2925, C-7025). The cells are incubated for 30 minutes and the working solution is replaced with fresh media afterwards. Preparation of the cells for use involves exposing cells to a 3 mL solution containing fluorescent probe (CellTracker™ Probes by Molecular Probes, C-2925, C-7025). The cells are incubated for an additional 30 minutes. Cells are detached using 0.25% trypsin, 1% EDTA, pelleted, counted and resuspended in serum free media at a concentration of 1×10^6 cells/mL. The cells are seeded on top of the hydrogels in a volume of 300 μ L. The lower wells are filled with 1000 μ L of supplemented media via the access ports.

Using National Instruments IMAQ Vision Builder 6, the percentage of migrated cells is determined as the average of three images. The cell area is represented as the percentage of the image area. ANOVA techniques will be performed using an $\alpha=0.05$ to determine significant difference between hydrogel ratios.

III. RESULTS

A. Synthesis of dextran hydrogel

Cross-linking of the conjugated dextran and acryloylated dextran produced white, opaque gels after exposure to UV for a few minutes. The pre-gel mixture remains a viscous liquid without addition of the photoinitiator.

B. Cell Migration Assay

The cell migration assay produced data with a noticeable trend to reduced cell migration with higher % of acryloylated dextran in relation to conjugated dextran. This is seen in Fig. 1. The data is presented as % image area covered by cells at three different timepoints. A-dex refers to acryloylated dextran and conjugated refers to conjugated dextran.

At four hours, there does not seem to be great difference between the mean values. Additionally, the variances appear large. There was no significant difference between the means using ANOVA for all the tested ratios. Significance was also found between the means for the 20% acryloylated dextran and 80% conjugated dextran blend and




Fig. 1. Percentage of cells covering the image area observed at 4, 24, and 48 hours. A-dex refers to acryloylated dextran and conjugated refers to conjugated dextran. The ratios are given in weight percentages.

the 60% acryloylated dextran and 40% conjugated dextran blend. The P-value, 0.033 is also less than the acceptable value of 0.05; this supports the assumption of significance.

The data at 24 hours are similar to the trend in the four hour results; however, there was found to be significance between all the means ($P = 0.00$). At this time, the percentage of cells migrating through the membrane without the gel barrier increased significantly. Significance was found between the 20% acryloylated dextran and 80% conjugated dextran blend and 80% acryloylated dextran and 20% conjugated dextran blend ($P = 0.00$).

At 48 hours, the same trend of decreasing cell migration with increasing acryloylated dextran is seen. However, statistically, the 40% acryloylated dextran and 60% conjugated dextran blend and 60% acryloylated dextran and 40% conjugated dextran blend ratios appear to be similar. The significance found between the 20% acryloylated dextran and 80% conjugated dextran blend and 80% acryloylated dextran and 20% conjugated dextran blend ($P = 0.00$) still held. At forty-eight hours, however, the percentage values seemed to decrease. This may be attributed in part to the loss of the dye through cell divisions.

IV. DISCUSSION

For the data taken at the four, twenty-four, and forty-eight hour time points, a general trend of cell migration can be noted. For comparison between means of two ratios, significant results can be determined. At the four hour mark, the differences between the ratios appear slight. Graphically, cell migration appears to decrease as the acryloylated dextran increases. The acryloylated dextran does not have the cleavable sites to allow cell migration. Expectedly, the number of cells going through the gel

should decrease as more of these sites are replaced by MMP stable cross-links. Fig. 1 shows cell migration range from 0.09 to 1.2% of the total image ratio and 1.5% for the wells without a gel. Although the differences in the means at the two extreme ratio values are significant, the results at this time point may be affected by cell response to initial seeding. Later time points revealed a more dramatic difference in cell migration.

At twenty-four hours, the amount of cell migration in the well without gel increased greatly. Without a gel as a barrier to the chemoattractants, the cells migrated at a much faster rate than the wells with a gel barrier. The range for the gel inserts increased to a 0.25 to 1.7%. The wells without gel increased to 13.6%. This data showed the most significant difference between the means for almost every analyzed combination. The difference between the two extremes (20 a-dex: 80 conjugated and 80 a-dex: 20 conjugated) is maintained, but other combinations showed significance also. Between the 20 a-dex: 80 conjugated and 40 a-dex: 60 conjugated ratios, the mean was found to be statistically different. At twenty-four hours, a greater cellular response is noted by increase in cells that came through the pores. The percentages did not seem to increase dramatically. For the highest proportion of conjugated dextran, cells migrated the most; however, the result does not seem to show much increase from the previous result taken at four hours. Looking at Fig. 1, the percentage of cells migrating through the gel did not increase greatly for each ratio. If a migration amount at less than 1% is desired, the three ratios, 40 a-dex: 60 conjugated, 60 a-dex: 40 conjugated, and 80 a-dex: 20 conjugated seem to fulfill this specification.

At forty-eight hours, cell migration seemed to decrease according to image analysis. The expected result would be increased cell migration. The range in cell migration in the inserts ranged from 0.1% to 0.7%, while the inserts without gel had 9.9% recorded. This deviation could be attributed to image analysis (threshold setting for cell count) or in the performance of the dye after two days. The concentration of cells (30,000 cells per 30 μ L) has not been found to be problematic in maintaining cell growth; however, in the division of cells, the intensity of the dye to be measured may be partitioned. Despite this, the general trend in decreased cell migration continues to hold. Statistical difference was found between the extreme ratio combinations again and between 40 a-dex: 60 conjugated and 80 a-dex: 20 conjugated. The use of conjugated dextran to allow cell migration appears to produce differential cell migration as expected.

The experiment was not conducted after forty-eight hours due to limited cell migration. The supplemented media would not maintain cell growth without replenishment after a couple of days. Also, the chemical

gradient created by the 10% serum found in the bottom of the cells may have equilibrated at this point. Without a force driving cell migration, no dramatic changes in invasion will be documented. This point may have affected the values at forty-eight hours.

The statistical analysis using ANOVA helped show which means in cell migration differed. A general analysis over the four ratios can determine whether the means differ; however, the separate comparisons over specific ratios would determine the significance between two. The 20 a-dex: 80 conjugated and 80 a-dex: 20 conjugated comparisons were always found to be significantly different. This result shows that cell migration is regulated by the incorporation of the cleavable peptide into the gel structure. Also, without a gel as a barrier, the cells showed increase migration. These analyses show the effectiveness of the gel as a barrier to migration and can show varying response to varying chemical composition of the hydrogel.

V. CONCLUSION

The following conclusions were drawn from this investigation:

- The amount of cell migration can be controlled by the number of cleavable sites introduced in a dextran hydrogel.
- Dextran ratios with higher proportions of acryloylated dextran limited the most cell migration.

For the different kinds of gels prepared from ratios of conjugated dextran and acryloylated dextran, the amount of cell migration was shown to be varied at three different time points. Although the means were not significant between all ratios among all three time points, significance was found between the ratios with greater proportions of conjugated dextran and acryloylated dextran. It appears that the peptide in conjugation with the dextran regulated the amount of cell migration through the hydrogel.

The results from this initial experiment demonstrated the possibility of controlling cell migration using a dextran hydrogel as a barrier. For therapeutic use, *in vivo* tests for biocompatibility need to be pursued to warrant medical application.

ACKNOWLEDGMENT

D.C. Hom would like to thank the support of the entire Massia lab for their help and expertise. Special thanks to Dr. Chad Kennedy and Dr. Gholam Ehteshami for all their help. Dr. Ron Nieman of the NMR facility was invaluable

for his NMR experiments. Thank-you to Dr. Daniel Brune and Dr. John Lopez for the synthesis of the peptide.

REFERENCES

- [1] S. Apple, J. Lindsay, *Principles and Practice of Interventional Cardiology*. Philadelphia, PA: Lippincott Williams & Williams. 2000 pp. 29-39.
- [2] E. R. Edelman, C. Rogers, "Pathobiologic responses to stenting," *Am. J. Cardiol.*, vol. 81, no. 7A, pp. 4E-6E, 1998.
- [3] J. Trudel, S. P. Massia, "Assessment of the cytotoxicity of photocrosslinked dextran and hyaluronan-based hydrogels to vascular smooth muscle cells," *Biomaterials.*, vol. 23, no. 16, pp. 3299-3307, Aug. 2002.
- [4] E. Schadht, B. Bogdanov, A. V. Den Bulcke, N. De Rooze, "Hydrogels prepared by crosslinking of gelation with dextran dialdehyde," *Reactive & Functional Polymers.*, vol. 33, no. 2, pp. 109-116, Aug. 1997.
- [5] W. N. E. van Dijk-Wolthuis, O. Franssen, H. Talsma, M. J. van Steenbergen, J. J. Kettenes-van den Bosch, W. E. Hennink, "Synthesis, characterization, and polymerization of glycidial methacrylate derivatized dextran," *Macromolecules.*, vol. 28, no 18, pp. 6317-6322, 1995.
- [6] B. K. Mann, A. S. Gobin, A. T. Tsai, R. H. Schmedlen, J. L. West, "Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering," *Biomaterials.*, vol. 22, no 22, pp. 3045-3051, Nov. 2001.

We claim:

1. A bioconjugate comprising dextran and a proteolytically cleavable peptide.
2. A drug delivery device comprising a bioconjugate of Claim 1 and a therapeutic drug.
3. A method of controlling migration of cells on a surface comprising contacting said cells with the bioconjugate of Claim 1.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/028000

International filing date: 27 August 2004 (27.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/499,634
Filing date: 28 August 2003 (28.08.2003)

Date of receipt at the International Bureau: 15 October 2004 (15.10.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse